Abstract 1449P
Background
KN046 is a novel bispecific domain antibody, which blocks both PD-L1 and CTLA-4. KN046 combined with platinum-based chemotherapy as 1L treatment for NSCLC had shown promising efficacy and tolerability in the previous clinical trial. (2022 ESMO 1029P). Herein, we present the promising preliminary data of KN046 combination with axitinib as 1L treatment for NSCLC.
Methods
Eligible subjects with recurrent/metastatic NSCLC, treatment-naive and PD-L1 expression ≥1% will be enrolled and receive KN046 5mg/kg IV Q3W and axitinib 5mg orally bid. This study adopts a Simon’s optimal two-stage design. In the 1st stage, 17 subjects will be enrolled, and the 2nd stage enrollment will be discontinued if objective response (CR or PR) observed in less than 5 subjects. Otherwise, 37 subjects will be enrolled in the 2nd stage. The primary endpoint is ORR. The secondary endpoints include DoR, safety, PFS and OS.
Results
As of data cut-off date (Mar 17, 2023), 22 subjects were enrolled, the median age was 64.5y (min:37, max:73), 90.9% were male. ECOG score was 0 (4.5%) and 1 (95.5%). PD-L1 expression was ≥50% in 22.7% of the subjects. 15 subjects completed at least one tumor assessment. In the efficacy analysis set, the ORR was 66.7% (10/15). The median follow-up for DoR was 4.21 m (95% CI,1.22, NE). The 3-m DoR rate was 100% (95% CI, 100.00, 100.00). The median study follow-up was 2.83 m (95% CI,0.72, 5.12). The 6-m PFS rate was 76.6 % (95% CI, 41.16, 92.28), The mPFS and mOS was not reached. The incidence of TEAE was 81.8% (18/22), of which KN046-related TRAE was 63.6% (14/22). Majority was grade 1-2. The incidence of KN046-related CTCAE Grade ≥3 TRAE was 9.1% (2/22). The most frequent TRAE was AST increased 9.1% (2/22) and ALT increased 4.5% (1/22). The incidence of irAE was 13.6% (3/22), No CTCAE Grade ≥3 irAE was found. There was no KN046-related death.
Conclusions
KN046 combined with axitinib is well tolerated and has shown very promising efficacy and safety signal in 1L treatment for advanced NSCLC. The 2nd stage of enrollment is ongoing and a phase 3 RCT is planned to further confirm the clinical benefit of KN046 and axitinb combo as a viable chemo free option for the 1st line NSCLC patient.
Clinical trial identification
NCT05420220.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Jiangsu Alphamab Biopharmaceuticals Co.,Ltd., Suzhou, China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1422P - Comprehensive genomic profiling (CGP) changes management and improves survival in patients with advanced non-small cell lung cancer (aNSCLC)
Presenter: George Simon
Session: Poster session 20
1423P - Clinical impact of radiological diagnosis of lymphangitic carcinomatosis in patients with extensive non-small cell lung cancer treated with immunotherapy
Presenter: Anita Bolina
Session: Poster session 20
1424P - Outcome of thromboembolic events and its influence on survival time of advanced NSCLC patients receiving antiangiogenic therapy
Presenter: Wei-Fan Ou
Session: Poster session 20
1425P - Clinical utility of liquid biopsy for the early diagnosis of EGFR mutant advanced lung cancer in real-life setting (CLEAR)
Presenter: Rola El Sayed
Session: Poster session 20
1427P - Exploration of the value of leptomeningeal biopsy in diagnosing and treating non-small cell lung cancer with leptomeningeal metastasis
Presenter: Lin Cai
Session: Poster session 20
1428P - Clinical benefit of combination chemo-immunotherapy in first-line treatment for patients over the age of 65 or 75 with metastatic NSCLC
Presenter: Thierry Landre
Session: Poster session 20
1429P - Homologous recombination repair (HRR) gene mutation: A novel biomarker for precision genomics testing in advanced lung cancer
Presenter: Madhu Nagaraj
Session: Poster session 20
1430P - Excellent performance of a fast and fully-automated RNA based genefusion assay conducted on a large fusion positive non-small cell lung cancer cohort within a multicenter study
Presenter: Arndt Hartmann
Session: Poster session 20
1431P - The nNGM Preclinical Platform: Preclinical research to generate evidence for patients with non-small cell lung cancer harboring variants of unknown significance
Presenter: Martin Ziegler
Session: Poster session 20